FELIQS

Japan · Biotech

FELIQS develops small-molecule medicines for retinal diseases.

Product

FELIQS is a Japanese biotechnology company developing small-molecule medicines that target oxidized lipids. Its lead programme, FLQ-101, is being developed to prevent retinopathy of prematurity, an eye disease affecting premature infants.

Founded in Kurume in 2019, the company builds on research into lipid oxidation. It is advancing FLQ-101 through US clinical development and established a US headquarters in 2025.

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A total including extension$10MBeyond Next Ventures, Inc. — LeadFFG Venture Business Partners, Inc. — ParticipantJapan Science and Technology Agency — ParticipantKeio Innovation Initiative — ParticipantMitsubishi UFJ Capital Co., Ltd. — Participant
Sourcesjst.go.jp ↗feliqs.com ↗